Adm |
25026 |
Protein administration |
Accelerated wound closure |
Adrb1 |
24925 |
Antagonist administration |
Delayed contraction in propranolol- and atenolol-treated animals but not in phentolamine-treated animals; re-epithelialization was decreased only in propranolol-treated animals |
Adrb2 |
24176 |
Antagonist administration |
Delayed contraction in propranolol- and atenolol-treated animals but not in phentolamine-treated animals; re-epithelialization was decreased only in propranolol-treated animals |
Agt |
24179 |
Protein administration |
Accelerated wound closure |
Ankrd1 |
27064 |
Overexpression |
Increased vascular component in granulation tissue |
C3 |
24232 |
Protein administration |
Increased maximal breaking strength; increased fibroblast and collagen deposition; additive hemostatic effect with the C3C5 combination |
C5 |
362119 |
Protein administration |
Increased maximal breaking strength; accelerated wound healing; increased vascular permeability, increased inflammatory cell recruitment, subsequent fibroblast migration, and increased collagen deposition |
C5 |
362119 |
Protein administration |
Increased maximal breaking strength; increased fibroblast and collagen deposition; additive hemostatic effect with the C3C5 combination |
Cfh |
155012 |
Protein administration |
Accelerated wound closure |
Egf |
25313 |
Overexpression |
Flap survival was enhanced by 14%, and was accomplished without accessing the arterial inflow of the territory |
Egf |
25313 |
Protein administration |
Accelerated wound closure; Accelerated epidermal proliferation |
Egf |
25313 |
Protein administration |
Promotion of wound healing |
Egf |
25313 |
Protein administration |
Accelerated re-repithelialization |
Epo |
24335 |
Protein administration, antibody treatment |
Protein administration: Increased granulation tissue formationr; Receptor or neutralizing antibody administration: inhibited granulation tissue formation |
Epor |
24336 |
Protein administration, antibody treatment |
Protein administration: Increased granulation tissue formationr; Receptor or neutralizing antibody administration: inhibited granulation tissue formation |
F2 |
29251 |
Peptide administration |
Accelerated wound closure in both normal and ischemic skin |
Fgf10 |
25443 |
Protein administration |
Accelerated re-epithelialization in the meshed skin graft model; more rapid gain in breaking strength of surgical incisions |
Fgf2 |
54250 |
Protein administration |
Increased α-SMA up to day 18 and then caused a decrease |
Fgf2 |
54250 |
Antibody treatment |
Reduced collagen content |
Fgf7 |
29348 |
Overexpression (liposomal gene transfer) |
Increased re-epithelialization; improved dermal regeneration; increased neovascularization |
Hgf |
24446 |
Protein administration |
Accelerated re-epithelialization in diabetic rats; increased expressions of the cell adhesion molecules β1-integrin and the cytoskeleton remodeling protein integrin-linked kinase (ILK) in epidermal cells |
Hpse |
64537 |
Protein administration |
Accelerated wound healing and improved FLAP survival; enhanced wound re-epithelialization and blood vessel maturation |
Igf1 |
24482 |
Overexpression (in exogenous fibroblasts) |
More organised granulation tissue formation; increased number of keratinocytes |
Igf1 |
24482 |
Overexpression (liposomal gene transfer) |
Improved dermal regeneration by an increased collagen deposition and morphology; increased VEGF concentrations and neovascularization |
Itgb2 |
309684 |
Antibody treatment |
Improved flap survival; decreased dermal and anastomotic myeloperoxidase activity |
Lama3 |
307582 |
Peptide administration |
Accelerated re-epithelialization; reduced inflammatory cell infiltration; enhanced fibroblast proliferation |
Lep |
25608 |
Protein administration |
Increased granulation tissue; improved angiogenesis; better flap survival |
Lox |
24914 |
Gene activated matrix |
Enhanced mechanical strength of the wound site |
Mmp8 |
63849 |
Overexpression |
Impaired wound healing by decreased collagen deposition and breaking strength; decreased number of neutrophils |
Ngf |
310738 |
Protein administration |
Accelerated wound healing, re-epithelialization, formation of granulation tissue, and collagen production |
Pdgfb |
24628 |
Protein administration |
Accelerated wound healing; Accelerated degradation of the polymer and enhanced formation of new granulation tissue as early as day 3 |
Proc |
25268 |
Protein administration |
Enhanced wound healing |
Tgfb1 |
59086 |
Antibody treatment, protein administration |
Neutralising TGF-beta 1: reduced the monocyte and macrophage profile, neovascularisation, fibronectin, collagen III and collagen I deposition in the early stages of wound healing; improved the architecture of the neodermis to resemble that of normal dermis and reduced scarring; effect was stronger when comined with TG-beta 2 neutralization; Protein treatment: more extracellular matrix deposition in the early stages of wound healing but did not differ from control wounds in the final quality of scarring |
Tgfb1 |
59086 |
Protein administration |
Accelerated wound healing; Increased wound breaking strength; increased influx of mononuclear cells and fibroblasts; increases in collagen deposition |
Tgfb2 |
81809 |
Antibody treatment, protein administration |
Neutralising TGF-beta 2 alone had no effect; combined with TGF-beta 1, it reduced the monocyte and macrophage profile, neovascularisation, fibronectin, collagen III and collagen I deposition in the early stages of wound healing; markedly improved the architecture of the neodermis to resemble that of normal dermis and reduced scarring; by contrast, wounds treated with either TGF-beta 1 or with TGF-beta 2 had more extracellular matrix deposition in the early stages of wound healing but did not differ from control wounds in the final quality of scarring |
Tgfb3 |
25717 |
Protein administration |
Reduced the monocyte and macrophage profile, fibronectin, collagen I and collagen III deposition in the early stages of wound healing and improved the architecture of the neodermis and reduced scarring |
Tgfbr2 |
81810 |
Overexpression |
Inhibited inflammatory reaction with reduced inflammatory cells; reduced scarring area |
Tmsb4x |
81814 |
protein dimer administration |
Accelerated wound healing |
Vegfa |
83785 |
Overexpression (local plasmid injection) |
Increased skin flap perfusion; increase in skin flap healing and survival |